Cargando…

Randomized Trial of Safety and Effectiveness of Chlorproguanil-Dapsone and Lumefantrine-Artemether for Uncomplicated Malaria in Children in The Gambia

BACKGROUND: Chlorproguanil-dapsone (Lapdap), developed as a low-cost antimalarial, was withdrawn in 2008 after concerns about safety in G6PD deficient patients. This trial was conducted in 2004 to evaluate the safety and effectiveness of CD and comparison with artemether-lumefantrine (AL) under cond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dunyo, Samuel, Sirugo, Giorgio, Sesay, Sanie, Bisseye, Cyrille, Njie, Fanta, Adiamoh, Majidah, Nwakanma, Davis, Diatta, Mathurin, Janha, Ramatoulie, Sisay Joof, Fatou, Temple, Beth, Snell, Paul, Conway, David, Walton, Robert, Cheung, Yin Bun, Milligan, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110183/ https://www.ncbi.nlm.nih.gov/pubmed/21666744 http://dx.doi.org/10.1371/journal.pone.0017371

Ejemplares similares

An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
por: Owusu-Agyei, Seth, et al.
Publicado: (2008)

Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
por: Bell, David J, et al.
Publicado: (2009)

Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria
por: Premji, Zul, et al.
Publicado: (2009)

Open-Label Comparative Clinical Study of Chlorproguanil−Dapsone Fixed Dose Combination (Lapdap™) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria
por: Wootton, Daniel G., et al.
Publicado: (2008)

Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
por: Belew, Sileshi, et al.
Publicado: (2020)

Prevention of the Recurrence of Anaemia in Gambian Children Following Discharge from Hospital
por: Bojang, Kalifa A., et al.
Publicado: (2010)

High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency
por: Fanello, Caterina I., et al.
Publicado: (2008)

Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria
por: Van Malderen, Carine, et al.
Publicado: (2012)

The clinical efficacy of artemether/lumefantrine (Coartem(®))
por: Makanga, Michael, et al.
Publicado: (2009)

Sustained Ex Vivo Susceptibility of Plasmodium falciparum to Artemisinin Derivatives but Increasing Tolerance to Artemisinin Combination Therapy Partner Quinolines in The Gambia
por: Amambua-Ngwa, Alfred, et al.
Publicado: (2017)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
por: Ali, Shabana, et al.
Publicado: (2010)

Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis
por: Prah, James, et al.
Publicado: (2016)

Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
por: Ehrhardt, Stephan, et al.
Publicado: (2009)

Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019
por: Dimbu, Pedro Rafael, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria
por: Tchaparian, Eskouhie, et al.
Publicado: (2016)

Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants
por: Poirot, Eugenie, et al.
Publicado: (2015)

Asymptomatic Plasmodium falciparum carriage and clinical disease: a 5-year community-based longitudinal study in The Gambia
por: Ahmad, Abdullahi, et al.
Publicado: (2023)

The Use of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium vivax Malaria
por: Bassat, Quique
Publicado: (2011)

Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India
por: Valecha, Neena, et al.
Publicado: (2009)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Artemether/Lumefantrine for the Treatment of P. malariae in a Patient on Hemodialysis
por: Patrocínio-Jesus, Rita, et al.
Publicado: (2019)

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali
por: Diarra, Modibo, et al.
Publicado: (2021)

Adverse reaction to Coartem (artemether/lumefantrine) resulting in oculogyric crisis
por: Amponsah, Emmanuel Kofi, et al.
Publicado: (2021)

Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
por: Nyangulu, Wongani, et al.
Publicado: (2023)

Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda
por: Ocan, Moses, et al.
Publicado: (2023)

Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria
por: Chotsiri, Palang, et al.
Publicado: (2019)

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
por: Peto, Thomas J, et al.
Publicado: (2022)

Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution
por: Janha, Ramatoulie E, et al.
Publicado: (2014)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
por: Sipilanyambe, Naawa, et al.
Publicado: (2008)

Malaria case-management under artemether-lumefantrine treatment policy in Uganda
por: Zurovac, Dejan, et al.
Publicado: (2008)

Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
por: Gürkov, Robert, et al.
Publicado: (2008)

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children
por: Abdulla, Salim, et al.
Publicado: (2009)

Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
por: Ogutu, Bernhards, et al.
Publicado: (2010)

Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania
por: Mugoyela, V, et al.
Publicado: (2011)

Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule
por: Patel, A., et al.
Publicado: (2012)

Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda
por: Rulisa, Stephen, et al.
Publicado: (2012)

Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort
por: Mosha, Dominic, et al.
Publicado: (2014)

A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission
por: Makanga, Michael
Publicado: (2014)

Monitoring the efficacy of artemether-lumefantrine for the treatment of uncomplicated malaria in Malawian children
por: Dambe, Rosalia, et al.
Publicado: (2015)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f7ts3is98i3tm189gsqevdpifk